Halozyme Therapeutics, Inc. (HALO) Institutional Ownership

Ownership Summary

Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed up in the 13F filings of 595 institutional investors as of December 2025.

• They owned 102.3% of outstanding stock in December 2025, down from 125.5% the prior quarter.
• Their total shares held in HALO increased 6.98% quarter over quarter, and separately, investors owning Halozyme Therapeutics increased 19.48% from a year ago.
• Of these 595 holders, 317 added to their stakes in Halozyme Therapeutics, 215 trimmed positions, and 63 made no changes.
• Institutional investors collectively held 125.11Mn shares in Halozyme Therapeutics as of December 2025, up by 8.17Mn shares quarter on quarter, and down 2.04Mn shares year over year.
• BlackRock, Inc. holds the largest position in HALO at 13.27Mn shares as of December 31, 2025, or 10.85% of shares outstanding.
• The largest buyers of Halozyme Therapeutics for the quarter ending December 2025 were VANGUARD CAPITAL MANAGEMENT LLC (5.27Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.25Mn), Boston Partners (2.2Mn), Janus Henderson Group Plc (1.6Mn), TWO SIGMA INVESTMENTS, LP (867.59K).
• The largest sellers of Halozyme Therapeutics for the quarter ending December 2025 were ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (1.3Mn), FULLER & THALER ASSET MANAGEMENT, INC. (1.29Mn), MILLENNIUM MANAGEMENT LLC (992.66K), Empowered Funds, LLC (637.36K), NATIXIS (466.29K).
• Halozyme Therapeutics's 10 largest shareholders as of December 2025 include BlackRock, Inc. (13.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.27Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (5.25Mn), State Street Corp (4.94Mn), Invesco Ltd. (4.01Mn), Bank Of America Corp /De/ (2.91Mn), Boston Partners (2.68Mn), Morgan Stanley (2.56Mn), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (2.53Mn), GEODE CAPITAL MANAGEMENT, LLC (2.51Mn) per Business Quant data.